Navigation Links
Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
Date:9/8/2008

PRINCETON, N.J., Sept. 8 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced that it received a milestone payment for an undisclosed amount from its licensing partner, Pfizer Inc. (NYSE: PFE). This payment is a result of the submission of an Investigational New Drug (IND) application by Pfizer for the clinical development of an antibody generated by Medarex's UltiMAb(R) technology. Medarex may receive future milestone payments and royalties should this product candidate progress through clinical development and to the market.

"We are pleased with the progress that Pfizer has made in advancing this antibody, generated using our UltiMAb(R) technology, towards the clinic," said Howard H. Pien, President and CEO of Medarex. "The continued development progress by Pfizer and our other partners reinforces the potential of products generated using our UltiMAb(R) antibody technology to treat life-threatening diseases."

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its Web site at http://www.medarex.com.

Medarex Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed herein may constitute forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential" or "may" or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. These risks and uncertainties include those detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and its quarterly reports on Form 10-Q. There can be no assurance that such development efforts will succeed or that other developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex's public disclosure filings are available from its investor relations department.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
2. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
3. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
4. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
5. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
6. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
7. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
8. Medarex Announces Ipilimumab Program Continues to Move Forward
9. Medarex to Receive Milestone Payment from Amgen
10. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
11. Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... TOWN, South Africa , Feb. 20, 2017 /PRNewswire/ ... of illness and non-communicable diseases (NCDs) across sub-Saharan Africa, ... prescription drugs. The growing incidence of more Western lifestyle ... respiratory disease, in addition to infectious and parasitic illness, ... with a business opportunity of $40.8 billion ...
(Date:2/20/2017)... SAN FRANCISCO , February 20, 2017 /PRNewswire/ ... (CSF) management market  is anticipated to reach USD ... report by Grand View Research, Inc. Constant evaluation ... hydrocephalus management is expected to drive growth in ... the investment for development of novel and improved ...
(Date:2/20/2017)... 20, 2017 Acute, Chronic and Prophylaxis GVHD ... at a CAGR of 7% from 2016-2021 and CAGR of 3% from ... from 2016 to 2027. The market is estimated at $0.36bn in 2016, ... ... discover how you can exploit the future business opportunities emerging in this ...
Breaking Medicine Technology:
(Date:2/18/2017)... La. (PRWEB) , ... February 18, 2017 , ... ... released today provides the latest information and contact points to easily connect elderly ... home care, assisted living, and elder-care funding. It also conveys material on this ...
(Date:2/17/2017)... Murfreesboro, TN (PRWEB) , ... February 17, 2017 ... ... EHR mobility has not kept pace. Enovate Medical has introduced an innovative workstation ... 20 years of supporting nurses, the Encore Mobile EHR Workstation offers a lightweight, ...
(Date:2/17/2017)... FL (PRWEB) , ... February 17, 2017 , ... ... software tools that allow for the electronic prescribing of controlled and non-controlled substances ... , Ninety percent of pharmacies in the United States now accept electronic prescriptions, ...
(Date:2/17/2017)... Falls Church, VA (PRWEB) , ... ... ... to Integrate FDA Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. ... , What are the critical reimbursement questions manufacturers should be asking ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... to Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 ... manufacturers distinguish between corrective action (CA) and preventive action (PA)? , The methods ...
Breaking Medicine News(10 mins):